Alpha 2.0
Login Register
» Authors » Liangcheng Zhu

Liangcheng Zhu

Explore the profile of Liangcheng Zhu including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 105
Followers 0
Related Specialties
Biochemistry
Chemistry
General Medicine
Top 10 Co-Authors
Zelin Sheng
Ajith Welihinda
Binhua Lv
Yuanwei Chen
Wenbin Zhang
Kun Peng
Brian Seed
Haifeng Ding
Jiyan Du
Baihua Xu
Published In
Bioorg Med Chem Lett
PLoS One
Bioorg Med Chem
J Med Chem
Pharmacol Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides
Zhou Z, Hu T, Xu Z, Lin Z, Zhang Z, Feng T, et al.
FASEB J . 2014 Nov; 29(2):724-32. PMID: 25384421
Hippo signaling pathway is emerging as a novel target for anticancer therapy because it plays key roles in organ size control and tumorigenesis. As the downstream effectors, Yes-associated protein (YAP)-transcriptional...
2.
Design, synthesis, and biological evaluation of deuterated C-aryl glycoside as a potent and long-acting renal sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes
Xu G, Lv B, Roberge J, Xu B, Du J, Dong J, et al.
J Med Chem . 2014 Jan; 57(4):1236-51. PMID: 24456245
SGLT2 inhibitors deuterated at sites susceptible to oxidative metabolism were found to have a slightly longer tmax and half-life (t1/2), dose-dependent increase in urinary glucose excretion (UGE) in rats, and...
3.
Small molecule R1498 as a well-tolerated and orally active kinase inhibitor for hepatocellular carcinoma and gastric cancer treatment via targeting angiogenesis and mitosis pathways
Zhang C, Wu X, Zhang M, Zhu L, Zhao R, Xu D, et al.
PLoS One . 2013 Jun; 8(6):e65264. PMID: 23755206
Protein kinases play important roles in tumor development and progression. Lots of kinase inhibitors have entered into market and show promising clinical benefits. Here we report the discovery of a...
4.
C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes
Xu B, Feng Y, Cheng H, Song Y, Lv B, Wu Y, et al.
Bioorg Med Chem Lett . 2011 Jul; 21(15):4465-70. PMID: 21737266
A series of C-aryl glucosides with various substituents at the 4'-position of the distal aryl ring have been synthesized and evaluated for inhibition of hSGLT1 and hSGLT2. Introduction of alkyl...
5.
EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA(1c) levels in db/db mice and prolongs the survival of stroke-prone rats
Zhang W, Welihinda A, Mechanic J, Ding H, Zhu L, Lu Y, et al.
Pharmacol Res . 2011 Jan; 63(4):284-93. PMID: 21215314
Sodium glucose co-transporter 2 (SGLT2) is a renal type III integral membrane protein that co-transports sodium and glucose from filtrate to epithelium in the proximal tubule. Human subjects with homozygous...
6.
ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors
Xu B, Feng Y, Lv B, Xu G, Zhang L, Du J, et al.
Bioorg Med Chem . 2010 Jun; 18(12):4422-32. PMID: 20576578
A series of 2-substituted C-aryl glucosides have been synthesized and evaluated for inhibition of hSGLT1 and hSGLT2. Introduction of an appropriate ortho substituent at the proximal phenyl ring adjacent to...
7.
Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors
Lv B, Xu B, Feng Y, Peng K, Xu G, Du J, et al.
Bioorg Med Chem Lett . 2009 Nov; 19(24):6877-81. PMID: 19896374
A series of novel O-spiroketal C-arylglucosides have been prepared and evaluated in cell-based functional assays for activity against human sodium-dependent glucose co-transporters 1 and 2 (SGLT1 and 2). The core...